Related Stories
Progress
For Sopharma AD this effort is another contribution to an excellent corporate governance file.
| Distribution of sales revenues by geographic region | |
|---|---|
| % | |
| Europe | 33 |
| Bulgaria | 65 |
| Other | 2 |
The contribution of sales in Bulgaria to the consolidated sales revenue in the first half of 2020 amounted to 65%, increasing by 10% compared to the first half of 2019. Sopharma has a 3% share on the Bulgarian pharmaceutical market in terms of value and a 10 % share in terms of sold quantity (units):
- Novartis: 6.6% (3.6% in units)
- Roche: 6.8% (0.3 in units)
- Actavis: 4.3% (9% in units)
- GlaxoSmithKlein: 2.9% (2.4% in units)
- Abbvie: 3.8% (0% in units)
- Sanofi-Aventis: 2.6% (2% in units)
- Astra Zeneca: 2.8% (0.4% in units)
- Pfizer: 4% (1% in units)
- Merck: 4.2% (0.8% in units)